Drug interactions
Efgartigimod alfa + Ipilimumab
Severity: Moderate
Efgartigimod alfa and Ipilimumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Ipilimumab is an IgG1 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
What this interaction means in plain words
Efgartigimod alfa and Ipilimumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Efgartigimod alfa belongs to Miscellaneous; Ipilimumab belongs to Oncology.
Why it happens
Efgartigimod blocks FcRn-mediated IgG recycling, which may accelerate catabolism of IgG-based ipilimumab.
What to do
Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Involve oncology and neurology specialists in weighing alternatives.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Efgartigimod alfa and Ipilimumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ipilimumab
Other interactions of Efgartigimod alfa
- Adalimumab + Efgartigimod alfa Moderate
- Ado-trastuzumab + Efgartigimod alfa Moderate
- Basiliximab + Efgartigimod alfa Moderate
- Bevacizumab + Efgartigimod alfa Moderate
- Brentuximab + Efgartigimod alfa Moderate
- Denosumab + Efgartigimod alfa Moderate
Frequently asked questions
Can I take Efgartigimod alfa with Ipilimumab?
MediHelp rates the interaction as moderate. Efgartigimod alfa and Ipilimumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Ipilimumab is an IgG1 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
How serious is the interaction between Efgartigimod alfa and Ipilimumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Involve oncology and neurology specialists in weighing alternatives.
What other medicines interact with Ipilimumab?
MediHelp also lists interactions of Ipilimumab with, for example, Etrasimod, Vemurafenib, Ciltacabtagene autoleucel. The full list is on the Ipilimumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
